In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
|Videos|December 7, 2016
What Should Pharmacists be Aware of When Treating Patients with Epilepsy?
Jacqueline A. French, MD—professor of neurology, NYU Comprehensive Epilepsy Study Consortium, president, The Epilepsy Study Consortium—discusses what pharmacists should keep in mind when treating patients with epilepsy.
Advertisement
Jacqueline A. French, MD—professor of neurology, NYU Comprehensive Epilepsy Study Consortium, president, The Epilepsy Study Consortium—discusses what pharmacists should keep in mind when treating patients with epilepsy.
Advertisement
Related to this article
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Prescription Volume: Measuring the Pharmacist’s Value
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
4
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
5